Health Canada has cleared Novo Nordisk’s diabetes drug Ozempic to reduce the risk of kidney failure, slow chronic kidney disease progression and cut cardiovascular mortality in adults with type 2 diabetes. The regulator said it approved the once-weekly semaglutide injection on 13 Aug., making Ozempic the first GLP-1 therapy in Canada authorised to protect both renal and heart function in this patient group. The decision was supported by results from the global FLOW trial, which followed 3,533 people with type 2 diabetes and chronic kidney disease for an average 3.4 years. Patients receiving Ozempic saw a 24 percent reduction in major kidney-disease events—defined as kidney failure, a 50 percent decline in filtration rate or death from renal or cardiovascular causes—compared with placebo, on top of standard treatments. Canada’s clearance comes months after the U.S. Food and Drug Administration awarded the same indication, expanding commercial prospects for one of Novo Nordisk’s fastest-growing products. Ozempic, already widely prescribed to control blood-sugar levels and aid weight loss, generated sales of $XX billion last year; analysts expect the broader label to lift demand further as physicians seek ways to delay dialysis and transplants.
Health Canada approves Ozempic to reduce kidney deterioration in people with diabetes https://t.co/Apz0bZOyeq https://t.co/VssKuHn2kH
$NVO'S OZEMPIC WINS CANADIAN APPROVAL FOR KIDNEY DISEASE Novo Nordisk said Health Canada has approved Ozempic for reducing the risk of kidney failure, disease progression, and cardiovascular death in type 2 diabetes patients with chronic kidney disease. The decision makes
Canada approves Ozempic to reduce risk of diabetic kidney disease progression https://t.co/XpO3Mp43Rr https://t.co/XpO3Mp43Rr